Abstract: The present invention relates to PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit improved pharmacokinetic and biological activity in vivo.

Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.

Abstract: The present invention relates to the development of improved methods for treating erectile dysfunction associated with diabetes. Significantly, such dosing regimens can be combined with established methods for treating sexual dysfunction, including phosphodiesterase-5 (PDE5) inhibitors such as those sold under the trademark VIAGRA® to provide for significantly improved efficacy compared to the PDE5 inhibitor alone.

Abstract: Improved methods and kits for treating the long-term complications of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits can also maintain good glycemic control and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Abstract: Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Abstract: The present invention relates to the development of improved methods for treating erectile dysfunction associated with diabetes. Significantly, such dosing regimens can be combined with established methods for treating sexual dysfunction, including PDE5 inhibitors such as those sold under the trademark VIAGRA® to provide for significantly improved efficacy compared to the PDE5 inhibitor alone.

Abstract: The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.

Abstract: The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Abstract: Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.

Abstract: The invention features compositions comprising insulin and C-peptide and methods for treating diabetes, using such compositions. The invention further features compositions comprising insulin analogues and C-peptide and the uses thereof for treating diabetes.

Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.

Abstract: The present invention relates to the use of proinsulin C-peptide or a variant, derivative or fragment thereof in the manufacture of a medicament for reducing the OTc interval and the use of proinsulin C-peptide or a variant, derivative or fragment thereof in the manufacture of a medicament for reducing the risk of sudden death or ‘dead in bed’ syndrome; particularly in patients suffering from IDDM.

Abstract: The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.

Abstract: The present invention relates to peptides being the N-terminal fragment of human proinsulin C-peptide and having the sequence EAEDLQVGQVEL (SEQ ID No: 2) or a fragment or peptide derivative thereof retaining the functional ability of the N-terminal fragment to contribute to C-peptide activity, wherein said fragment or peptide derivative comprises two acidic amino acid residues and is capable of adopting a conformation where said two acidic amino acid residues are spatially separated from one another by a distance of 9-14 ? between the ?-carbons thereof; and wherein said peptide derivative does not include native C-peptide of any species nor human C-peptide 1-15, 1-24 or 1-26 or rat C-peptide 1-26. The invention also relates to peptides having an amino acid sequence comprising (i) the N-terminal fragment of human insulin C-peptide having the sequence EAEDLQVGQVEL (SEQ ID NO. 2) or (ii) a fragment or peptide derivative of amino acid sequence SEQ ID NO.

Abstract: The present invention relates to the use of proinsulin C-peptide or a variant, derivative or fragment thereof in the manufacture of a medicament for reducing the OTc interval and the use of proinsulin C-peptide or a variant, derivative or fragment thereof in the manufacture of a medicament for reducing the risk of sudden death or ‘dead in bed’ syndrome; particularly in patients suffering from IDDM.

Abstract: The invention features peptides that are fragments of the human insulin C-peptide, which peptides include the sequence ELGGGPGAG or a fragment thereof, or the sequence EGSLQ or a fragment thereof. The peptides have the ability to stimulate Na+K+ATPase activity. Also provided are biomimetic organic compounds exhibiting activation of Na+K+ATPase activity and/or cellular binding to renal tubule cells and fibroblasts. Such peptides and compounds are useful in combating diabetes and diabetic complications, or for stimulating Na+K+ATPase activity.

Abstract: The present invention relates to a peptide being a fragment of the human insulin C-peptide, said peptide comprising the sequence ELGGGPGAG or a fragment thereof, or the sequence EGSLQ or a fragment thereof, and having the ability to stimulate Na+K+ATPase activity.